Shenzhen Hepalink Pharmaceutical Group Statistics

Total Valuation

Shenzhen Hepalink Pharmaceutical Group has a market cap or net worth of HKD 16.63 billion. The enterprise value is 18.03 billion.

Market Cap	16.63B
Enterprise Value	18.03B

Important Dates

The next estimated earnings date is Wednesday, March 26, 2025.

Earnings Date	Mar 26, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.01%
Shares Change (QoQ)	-0.07%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	421.29M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	1.60
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 56.14, with an EV/FCF ratio of 7.70.

EV / Earnings	-111.24
EV / Sales	3.10
EV / EBITDA	56.14
EV / EBIT	n/a
EV / FCF	7.70

Financial Position

The company has a current ratio of 2.39, with a Debt / Equity ratio of 0.35.

Current Ratio	2.39
Quick Ratio	1.01
Debt / Equity	0.35
Debt / EBITDA	14.34
Debt / FCF	2.04
Interest Coverage	-0.58

Financial Efficiency

Return on equity (ROE) is -1.34% and return on invested capital (ROIC) is -0.34%.

Return on Equity (ROE)	-1.34%
Return on Assets (ROA)	-0.31%
Return on Capital (ROIC)	-0.34%
Revenue Per Employee	2.90M
Profits Per Employee	-77,914
Employee Count	2,080
Asset Turnover	0.29
Inventory Turnover	0.67

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +9.52% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+9.52%
50-Day Moving Average	4.24
200-Day Moving Average	3.47
Relative Strength Index (RSI)	45.70
Average Volume (20 Days)	987,050

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Shenzhen Hepalink Pharmaceutical Group had revenue of HKD 6.04 billion and -162.06 million in losses. Loss per share was -0.11.

Revenue	6.04B
Gross Profit	1.06B
Operating Income	-103.76M
Pretax Income	-246.23M
Net Income	-162.06M
EBITDA	295.97M
EBIT	-103.76M
Loss Per Share	-0.11

Full Income Statement

Balance Sheet

The company has 3.41 billion in cash and 4.77 billion in debt, giving a net cash position of -1.36 billion.

Cash & Cash Equivalents	3.41B
Total Debt	4.77B
Net Cash	-1.36B
Net Cash Per Share	n/a
Equity (Book Value)	13.53B
Book Value Per Share	9.16
Working Capital	6.68B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.69 billion and capital expenditures -343.71 million, giving a free cash flow of 2.34 billion.

Operating Cash Flow	2.69B
Capital Expenditures	-343.71M
Free Cash Flow	2.34B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 17.49%, with operating and profit margins of -1.72% and -2.68%.

Gross Margin	17.49%
Operating Margin	-1.72%
Pretax Margin	-4.08%
Profit Margin	-2.68%
EBITDA Margin	4.90%
EBIT Margin	-1.72%
FCF Margin	38.78%

Dividends & Yields

Shenzhen Hepalink Pharmaceutical Group does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.01%
Shareholder Yield	0.01%
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Shenzhen Hepalink Pharmaceutical Group has an Altman Z-Score of 2.4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.4
Piotroski F-Score	n/a